Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 4701–4750 of 75391
On May 19, 2025, Abhishek Khandelwal, Senior Vice President and Chief Financial Officer of IDEX Corporation (the “Company”), notified the Company of his decision to resign from his position, effective May 30, 2025, to pursue a new professional opportunity.
On May 21, 2025, MarketAxess Holdings Inc. (the “Company”) announced that it had appointed Dean Berry as its Group Chief Operating Officer and Chief Executive Officer, EMEA & APAC, effective as of his start date.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Kurtis Barker and Allison Spector resigned from the Company's Board of Directors (the "Board"), which became effective upon acceptance by the Unaffiliated Directors (as defined in the Stockholders Agreement) of the Board on May 21, 2025.
each of Kurtis Barker and Allison Spector resigned from the Company's Board of Directors (the "Board"), which became effective upon acceptance by the Unaffiliated Directors (as defined in the Stockholders Agreement) of the Board on May 21, 2025.
the Board elected Mr. Jiewei Li, the Company’s Chief Financial Officer, as a new director of the Company, effective immediately.
On May 20, 2025, Mr. Yunfei Li advised the Board of Directors (the “Board”) of CBAK Energy Technology, Inc. (the “Company”) of his resignation as a member and the Chairman of the Board, effectively immediately.
On May 16, 2025, the board of directors of Crocs, Inc. (the “Company”) approved a change in title and responsibilities for Terence Reilly, effective immediately. Mr. Reilly’s title changed from Executive Vice President, Brand President for HEYDUDE, to Executive Vice President, Chief Brand Officer.
In the meantime, Mr. Rees will serve as the interim President for the HEYDUDE brand until a permanent structure is announced.
On May 15, 2025, the Board of Directors (the “ Board ”) of the Company elected Terence R. Donnelly to the Board, effective May 27, 2025.
Farouq Tuweiq (“ Mr. Tuweiq ”), Bel’s current Chief Financial Officer (“ CFO ”), principal financial officer and Treasurer, was appointed to succeed Daniel Bernstein as the Company’s President and Chief Executive Officer, effective immediately following the Company’s 2025 Annual Meeting
the Board approved the expansion of the Board to ten directors and the appointment of Mr. Tuweiq as a director on the Board, effective as of the date of the 2025 Annual Meeting
On May 20, 2025, the Board appointed Lynn Hutkin (“ Ms. Hutkin ”), currently Bel’s Vice President of Financial Reporting and Investor Relations, as the Company’s new CFO, effective immediately following the 2025 Annual Meeting
Effective the same date, the Board of Directors appointed Vighnesh Dabole as Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer, and sole director of the Company.
Effective May 20, 2025, Frank Gomez resigned as Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer, and sole director of the Company.
On May 16, 2025, Michael Urlick informed Clearwater Paper Company (the “Company”) that he intends to resign from his position as Senior Vice President, Commercial of the Company to pursue a new opportunity.
Travis D. Stice stepped down as Chief Executive Officer of the Company and became Executive Chairman of the Board of Directors of the Company, in each case effective as of May 21, 2025
At the 2025 Annual Meeting, Mr. Van’t Hof was also elected to serve as a director of the Company until the 2026 Annual Meeting of Stockholders
Effective as of the date of the 2025 Annual Meeting, Kaes Van’t Hof, former President of the Company, succeeded Mr. Stice as Chief Executive Officer.
David L. Houston, who served as a director of the Company since the Company’s initial public offering, did not stand for re-election at the 2025 Annual Meeting and retired as a director and member of the Company’s Audit Committee and Safety, Sustainability and Corporate Responsibility Committee, effective as of the date of the 2025 Annual Meeting.
Beginning on the Effective Date, David A. Lunin will no longer serve as the Company’s principal accounting officer. Mr. Lunin will continue to serve as the Executive Vice President, Chief Financial Officer and principal financial officer of the Company.
the Board of Directors of the Company (the “Board”) has appointed John R. Krutz to serve as the Company’s Chief Accounting Officer and principal accounting officer, effective May 21, 2025
Skip Kiil would be assuming the role of EVP and President, Cardiovascular Portfolio
Sean Salmon would be departing from his position as EVP and President, Cardiovascular Portfolio
Mark Dmytruk, the Company’s Chief Financial Officer and principal financial officer, gave notice on May 19, 2025 of his intention to resign from these roles at the Company on May 30, 2025 to accept a position at another organization
Steven Coen, CPA, the Company’s Chief Accounting Officer, will become Chief Financial Officer, principal financial officer and principal accounting officer, effective upon Mr. Dmytruk’s resignation
Effective May 15, 2025, the Company appointed Alan Weichselbaum as the Chief Financial Officer of the Company.
Effective May 16, 2025, Michelle Yanez and the Company mutually agreed to release Ms. Yanez from her position as Chief Financial Officer, Treasurer and Secretary of MIRA Pharmaceuticals, Inc. (the “Company”), effective on that date.
Effective May 16, 2025, Michelle Yanez and the Company mutually agreed to release Ms. Yanez from her position as Chief Financial Officer, Treasurer and Secretary of Telomir Pharmaceuticals, Inc. (the “Company”), effective on that date.
On May 15, 2025, the Company entered into an Employment Agreement (the “Employment Agreement”) with Mr. Weichselbaum to serve as chief financial officer of the Company beginning on May 19, 2025 (the “Start Date”).
On May 20, 2025, the Company announced the appointment of Ms. Helena Santos as its interim CFO until a suitable candidate can be appointed by the Company’s Board of Directors.
Nicholas Lavacca, who had served as the Company’s CFO since April 18, 2025, left the Company on May 19, 2025 to pursue other opportunities.
On May 15, 2025, Kyle Burtnett gave the Board of Directors (the “Board”) of Southland Holdings, Inc. (“Southland” or the “Company”) notice of his resignation as a Director of Southland.
On May 19, 2025, the Board appointed Tan Parker as a Class I director to fill Mr. Burtnett’s vacant seat, thereby bringing the number of directors on the board back to seven, effective as of May 19, 2025.
approved the transition of Marcos Galperin, the Company’s President and Chief Executive Officer, to a more strategic role within the Company, as Executive Chairman of the Board, effective as of January 1, 2026.
As of the Effective Date, Ariel Szarfsztejn, the Company’s current Commerce President, will become President and Chief Executive Officer of the Company.
our stockholders elected Samuel A. DiPiazza, Jr., C.P.A., Maye Head Frei, and Scott C. Syphax to our Board of Directors
Kedrick D. Adkins, C.P.A., who had served on the Board for seven years, did not stand for re-election
our stockholders elected Samuel A. DiPiazza, Jr., C.P.A., Maye Head Frei, and Scott C. Syphax to our Board of Directors
our stockholders elected Samuel A. DiPiazza, Jr., C.P.A., Maye Head Frei, and Scott C. Syphax to our Board of Directors
appointed Andrew F. Walters as a member of the Board, effective as of July 1, 2025.
the Company appointed Mr. Walters, the Company's current Chief Financial Officer and Treasurer, to the position of Chief Executive Officer upon the retirement of Eric W. Thornburg as Chief Executive Officer and President of the Company, each effective July 1, 2025.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.